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Abstract 
Objective To describe and analyse the characteristics of oral cholera vaccination 
campaigns; including location, target population, logistics, vaccine coverage and 
delivery costs. 
Methods We searched PubMed, the World Health Organization (WHO) website 
and the Cochrane database with no date or language restrictions. We contacted public 
health personnel, experts in the field and in ministries of health and did targeted web 
searches. 
Findings A total of 34 documents were included in the analysis. One country, 
Viet Nam, incorporates oral cholera vaccination into its public health programme and 
has administered approximately 10.9 million vaccine doses between 1997 and 2012. In 
addition, over 2 million doses of the two WHO pre-qualified oral cholera vaccines have 
been administered in 16 campaigns around the world between 1997 and 2014. These 
campaigns have either been pre-emptive or reactive and have taken place under 
diverse conditions, such as in refugee camps or natural disasters. Estimated two-dose 
coverage ranged from 46 to 88% of the target population. Approximate delivery cost per 
fully immunized person ranged from 0.11–3.99 United States dollars. 
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Conclusion Experience with oral cholera vaccination campaigns continues to 
increase. Public health officials may draw on this experience and conduct oral cholera 
vaccination campaigns more frequently. 
Introduction 
Vibrio cholerae causes severe diarrhoea and the main strategies to prevent the disease are to 
promote hygiene and to ensure safe water and sanitation. These basic needs are often not met in 
endemic areas with seasonal cholera outbreaks or during man-made or natural disasters in 
impoverished areas. An additional tool for cholera prevention and control is the oral cholera 
vaccine. In October 2009, the World Health Organization (WHO) Strategic Advisory Group of 
Experts on immunization recommended that oral cholera vaccination should be considered as a 
reactive strategy during outbreaks, in addition to the already recommended preventive use of oral 
cholera vaccine in endemic areas.1 A vaccine stockpile was created in 2012, with an initial two 
million doses to be available mainly for epidemic response in low-income countries.2 In 
November 2013, the global alliance for vaccines and immunizations (Gavi Alliance) approved a 
financial contribution towards the stockpile to expand its use in outbreak situations and endemic 
settings. With the availability of the oral cholera vaccine stockpile, more governments might 
consider cholera vaccination where needed. 
A monovalent inactivated vaccine containing killed whole-cells of V. cholerae serogroup 
O1 and the B-subunit of cholera toxin was the first oral cholera vaccine to obtain international 
licensure in 1991 and WHO prequalification in 2001. The vaccine is marketed as Dukoral 
(Crucell, Netherlands). Randomized, placebo-controlled trials of earlier versions of Dukoral in 
Bangladesh and the current recombinant B-subunit whole cell vaccine in Peru showed that the 
vaccine is safe and confers an initial protection of approximately 85% in the first months.3,4 
Follow-up studies in Bangladesh estimated a 62% protection during the first year, 57% during 
the second year and negligible thereafter.3 
During the mid-1980s, the National Institute of Hygiene and Epidemiology in Viet Nam 
developed an oral cholera vaccine for the country’s public health programme. A two-dose 
regimen of a first-generation of monovalent (anti-O1) cholera vaccine had an estimated efficacy 
of 66% against the El Tor strain of V. cholerae.5 In 1997, the vaccine was augmented with killed 
V. cholerae serogroup O139 whole cells to create a bivalent vaccine,6 which was locally licensed 
as ORC-Vax (Vabiotech, Viet Nam). After changing production procedures in 2009, the vaccine 
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was reformulated and licensed as mORC-Vax (Vabiotech, Viet Nam) and is currently used in 
Viet Nam’s public health programme.7 However, the vaccine is not pre-qualified by WHO. 
To make the mORC-Vax internationally available, manufacture of the reformulated 
vaccine was transferred to Shantha Biotechnics Ltd in India, where the national regulatory 
authority is approved by WHO.8 This led to the development of Shanchol, which is the third 
currently-available oral cholera vaccine. A randomized, placebo-controlled trial in India showed 
that Shanchol is safe and confers 67% protective efficacy against cholera within two years of 
vaccination,8 66% at three years9 and 65% at five years10 of follow-up. Shanchol was licensed in 
India in 2009 and received WHO pre-qualification in 2011. 
A comparison of the three oral cholera vaccines is shown in Table 1.11,12 The safety, 
relative effectiveness and duration of protection of the different types of oral cholera vaccine has 
previously been reviewed.13 Here we conduct a systematic review of post-licensure oral cholera 
vaccination campaigns. The objective of the review is to generate information – by describing 
and analysing the campaigns – that can be used to inform planning for the future use of these 
vaccines. 
Methods 
Search 
We searched the Cochrane database of systematic reviews and their database of abstracts and 
reviews of effects from 1990 to present and found no reviews of oral cholera vaccination 
campaigns. 
We conducted a systematic review of published documents on post-licensure vaccination 
campaigns using one of three oral cholera vaccines following the search and analysis process 
recommended in the Preferred Reporting Items for Systematic Reviews and Met-analyses 
guidelines. We searched PubMed and the WHO web site using “cholera vaccination”, “cholera 
outbreak response” and “cholera vaccination campaign” as search terms with no date or language 
restrictions. The bibliographies of the retrieved articles were also screened for relevant papers. 
Reports, presentations and international organization or company documents were obtained 
through targeted web searches. We also contacted public health personnel, experts in the field 
and in ministries of health for further information.  
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All identified documents in English that described campaigns using oral cholera vaccine 
were assessed for appropriateness using the following selection criteria. We included all 
documents describing campaigns using Dukoral after 1991, ORC-Vax after 1997, mORC-Vax 
after 2009 and Shanchol after 2009. Campaigns organized either as part of a public health 
response to endemic or epidemic cholera, pilot campaigns, demonstration projects, assessments 
of feasibility and acceptability, as well as studies of vaccine effectiveness were included. Each 
campaign may have more than one reference, describing different aspects of the vaccination (e.g. 
feasibility, coverage, cost, etc.). We excluded documents describing pre-licensure trials, reports 
on knowledge and perception of cholera and oral cholera vaccines, as well as planning or policy 
briefs that did not describe actual oral cholera vaccine deployment. 
By adhering to the pre-defined inclusion and exclusion criteria, we could make a valid 
comparison across articles. To assess the broad picture of the vaccine campaigns, we did not 
exclude any document based on quality or deficiency of reporting. Information from the 
published and unpublished documents was extracted and entered into a spread sheet 
independently by two of the authors and then corroborated and summarized by a third author. 
Definitions 
Oral cholera vaccine campaigns can either be pre-emptive or reactive. Pre-emptive or preventive 
vaccination refers to campaign implementation before a cholera outbreak begins, ideally in 
conjunction with improved water, hygiene and sanitation. Pre-emptive vaccination may be 
conducted before the next seasonal outbreak in sites where cholera regularly occurs, in 
communities adjacent to an area with cholera or during humanitarian emergencies to prevent 
cholera. Reactive campaigns are those implemented after a cholera outbreak has started and 
while cholera cases are still being detected in the target population.14 In areas where cholera 
tends to occur all year-round, the distinction between pre-emptive and reactive vaccination may 
be difficult. 
The target population was defined as the number of individuals living in a circumscribed 
area to whom oral cholera vaccine is offered. The target population may be an estimate based on 
administrative population figures or more precise figure based on a study census. Coverage was 
defined as the percentage of the target population who received one dose and two doses (fully 
immunized) of the vaccine, except when otherwise indicated (i.e. community surveys were used 
to calculate vaccine coverage in some campaigns particularly when a precise target population 
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number was not known). The approximate total number of oral cholera vaccine doses deployed 
was defined as the sum of the first and second dose recipients; when data on the first dose 
recipients were not available, we multiplied the number of fully vaccinated individuals by two. 
We plotted the number of approximate doses deployed in oral cholera vaccine campaigns by 
country. Countries were colour-coded by the number of cholera cases reported in 2005,15 using 
ArcMap 10.0 (ESRI, Redlands, USA). Adverse events following immunization were defined as 
medical incidents that take place after an immunization and cause concern. Adverse events 
following immunization may be coincidental or causally associated. A serious adverse event 
following immunization is one that requires hospitalization and/or causes birth defects, 
permanent damage, or death. 
To allow comparison of the expenses for vaccination across various campaigns, the 
expenses were grouped into the following categories: vaccine and/or international shipment 
costs, computers and other capital expenses, international consultants, local storage and 
transport, meetings, social mobilization, training, local salaries, supplies and waste management 
and the detection and management of adverse events following immunization. The delivery cost 
per fully immunized person was calculated using the total local expenses (excluding vaccine, 
international shipment and consultant costs) as the numerator and the number of fully immunized 
persons as the denominator. 
Results 
We identified 174 unique documents of potential relevance and 34 of these met the inclusion 
criteria (Fig. 1).16–49 In addition, we obtained information about recent campaigns through 
personal communications with two co-authors (Stephen Martin and Kathryn Alberti). We 
mapped the approximate number of doses administered in post-licensure oral cholera vaccination 
campaigns from 1997 to 2014 (Fig. 2) and plotted them by year (Fig. 3). The characteristics and 
main findings of each vaccination campaign are shown in Table 2. For campaigns with detailed 
data available, the vaccination logistics by target population size is shown in Table 3. 
Dukoral 
About 526 017 doses of Dukoral were administered in six vaccination campaigns from 1997 to 
2009, all of which were pre-emptive (Table 2).16–30 These included two feasibility studies in 
refugee camps16,17,22,23 and one campaign following a natural disaster.23,24 The percentage of 
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fully immunized persons ranged from 50–88%. There were two effectiveness studies in sub-
Saharan Africa, which confirmed direct vaccine protection of 78–79%, 12 to 15 months 
following vaccination21,27, as well as herd protection.27 We found one document stating that 
137 000 Dukoral doses were delivered to Myanmar in 200825 but we were unable to find more 
information. 
The duration of the vaccination campaigns ranged from one to five months and consisted 
of two rounds at a 10- to 14-day interval (Table 3). Each round took 4 to 15 days.16,20,23,24,27 Cold 
chain for vaccine delivery was reportedly maintained at 2–8 °C from storage to administration in 
Beira, Mozambique20, Aceh, Indonesia24 and Zanzibar, United Republic of Tanzania.27 In 
Uganda, the vaccine was maintained at room temperature.16 Vaccination teams were able to 
vaccinate 100 to 609 persons per day. 16,20,23,24,27 Reported adverse events following 
immunization in Uganda and Mozambique were minor and non-specific.16,20 Delivery cost per 
fully immunized person ranged from 0.53 United States dollars (US$) to US$ 3.66 (Table 4). 
ORC-Vax and mORC-Vax 
In Viet Nam, an estimated 10.9 million doses of ORC-Vax and mORC-VAX have been deployed 
from 1997 to 2013 through targeted mass vaccination or – to children – through the Expanded 
Programme of Immunization in cholera-endemic regions.31–34 Documented coverage during the 
vaccination of half of the communes in Hue was 79% (118 703/149 557) in 1998 and 75% 
(103 226/137 082) in the other half in 2000; long term vaccine effectiveness (three to five years 
after the campaign) was 50%.31,32 (Table 2).Vaccine coverage was not precisely quantified in the 
2008 Hanoi campaign; vaccine effectiveness was 76.%33 The duration of the vaccination 
campaigns ranged from two to four weeks with each round taking 3 to 9 days (Table 3).31–33 
Mass campaigns are held yearly in Hue and are part of the routine public health provision, 
requiring minimal additional costs. The delivery cost in Hue during a 2013 campaign was 
US$ 0.11 per fully immunized person.34 
Shanchol 
Since WHO pre-qualification, Shanchol has been increasingly used in campaigns.35–49 About 
1 535 293 doses have been administered in ten campaigns (Table 2), three of which were 
described as reactive. The percentage of fully immunized persons ranged from approximately 
46–85% (Table 2). A study in Odisha, India 2011, found that oral cholera vaccination through 
the Indian public health system is feasible.35 The campaign in Dhaka, Bangladesh 2011, includes 
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an assessment of vaccine effectiveness with and without other interventions.36 The two 
vaccination campaigns in Haiti in 2012 were pilot projects that paved the way for the launching 
of a national cholera vaccination programme integrated in a long-term plan to address water 
safety and sanitation.37–41 There was third campaign in Haiti in 2013. Shanchol was deployed for 
pre-emptive vaccination in Solomon Islands, in 2012, following reports of cholera in a nearby 
area.42 The vaccination campaign in Thailand, 2012, was conducted to prevent seasonal 
outbreaks in a stable camp setting.43 The vaccination campaign in Guinea, 2012, was the first 
reactive oral cholera vaccine campaign in sub-Saharan Africa and the first time that Shanchol 
was used in an African setting.44–46 The campaigns in Guinea and in Maban county, South Sudan 
2013 confirmed that large-scale vaccinations under logistically difficult conditions are 
feasible.47,48 The campaign in internally displaced persons camps in South Sudan in 2014, was 
the first to use the oral cholera vaccine stockpile.49 
The Shanchol campaigns were conducted in 1–3 months.35–49 The 2012 Haiti campaign 
was carried out in two phases due to an overlapping national oral polio vaccination campaign.37–
41
 The number of persons vaccinated per day ranged from 774–1150.36,44–49 No serious adverse 
events following immunization were reported. In campaigns in Odisha, Dhaka and in Haiti in 
2012, cold chain for vaccine was maintained at 2–8 °C from storage to delivery at site.35–41 In the 
campaigns in Guinea and in 2013 in South Sudan cold chain was maintained until the day of 
vaccination, during which vaccines were transported to vaccination sites and used at ambient 
temperature44–48 (Table 3). 
The delivery costs of Shanchol through the existing government health system in 
Bangladesh and India were US$ 1.63 and US$ 1.13, respectively, per fully immunized 
person.35,36 The local expenses of reactive deployment in Guinea was US$ 1.97,46 while costs in 
Maban, South Sudan were US$ 3.99 per fully immunized person (Table 4).48 
Discussion 
We estimate that about 2 061 310 doses of Dukoral and Shanchol have been deployed in 
vaccination campaigns in areas affected by cholera around the world from 1997 to 2014. Only 
one country, Viet Nam, incorporates oral cholera vaccination into its public health programme 
and has used more than 10 million doses since 1997. Recently larger numbers of doses have been 
deployed in different areas globally but the vaccine is still under-used compared to the 1.4 billion 
people at risk of cholera in endemic areas.15 There is a shortage of licensed, WHO-prequalified 
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cholera vaccines to meet global endemic and epidemic needs and insufficient supply is often 
cited as an obstacle to wider vaccine use.50 Availability of an oral cholera vaccine stockpile may 
lead to a larger vaccine supply through more consistent and predictable demands and may help 
increase vaccine use. Insufficient vaccine supply can be addressed by encouraging manufacturers 
to increase production capacity. 
The deployments of oral cholera vaccine have previously been pre-emptive but recent 
experiences in Guinea and Haiti have shown that reactive mass vaccinations are feasible.37–41,44–
46
 The number of cases and deaths that can been prevented by reactive vaccination depends on 
the characteristics of the outbreak, with greatest impact during large and long-lasting outbreaks 
usually seen in populations with no recent exposure to the disease.14 With the development of an 
oral cholera vaccine stockpile and possibility of rapid deployment, increased reactive use of oral 
cholera vaccine is anticipated. 
To be able to compare the campaigns, we calculated the total delivery cost per fully 
immunized person by excluding the expenditures for vaccine, shipment and technical experts, 
but the estimates still varied considerably. Deployment costs were lowest in Hue, Viet Nam, 
where the vaccine is administered routinely through the public health system31,34 but a similar 
delivery strategy may not be possible in other cholera-endemic areas or during the acute phase of 
emergencies. The requirement for co-administration of a buffer with the Dukoral vaccine 
complicates the delivery of such vaccine and likely increases its delivery costs. Both mORC-Vax 
and Shanchol do not require a buffer, which should streamline the delivery and reduce logistical 
requirements. 
This analysis has several limitations. First, there was a wide variation in the methods used 
to calculate coverage and costs in the vaccination campaigns. Some coverage estimations were 
precise, while others were approximations. Although we attempted to make the costing 
comparable, the calculated figures should be interpreted with caution. There are large variations 
in the costing of some items that cannot merely be explained by differences in site conditions and 
access. There are also local variables such as distance from central storage to the vaccine 
administration sites, campaign duration and vaccine storage conditions that affect the costs. 
Variations in campaign logistics also influence the estimates. Differences may also arise from the 
methods used to calculate expenses. For future campaigns, estimating cost using a standardized 
method would be very useful. Second, reporting was not consistent, as some information about 
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the campaign, such as coverage, delivery, adverse events following immunization monitoring 
and other details, were not always measured or reported. We obtained the least information on 
the oral cholera vaccine campaigns in the Comoros and the Solomon Islands. Third, the more 
recent post-licensure vaccination campaigns (for example in Ethiopia and Nepal) have not been 
included and will require updated reporting as information becomes available. Fourth, 29% 
(10/35) of documents included in the analysis were not published in peer-reviewed journals but 
were the only available sources of data for some of the vaccination campaigns. Fifth, many of the 
campaigns are done in collaboration between ministries of health and external health agencies 
(e.g. Médecins Sans Frontières, WHO, Partners for Health, United States’ Centers for Disease 
Control and Prevention). It will be important to continue to monitor and evaluate future 
campaigns using vaccine from the stockpile and implemented mainly by ministries of health. 
Despite these limitations, our findings provide important lessons. The number of oral 
cholera vaccination campaigns is increasing and experience has been documented in a variety of 
settings. The increasing use of oral cholera vaccine is reassuring but more needs to be done to 
encourage its use where needed. This increase will likely continue with the availability of an oral 
cholera vaccine stockpile and as more experience is gained with campaigns. Data from the 
deployments confirm the effectiveness, safety and feasibility of mass oral cholera vaccination. 
While the two-dose vaccination schedule may be perceived as an impediment to delivery and 
coverage, the experience with both Dukoral and Shanchol disproves this perception. In addition, 
community education on cholera control and distribution of other preventive measure such as 
soap and chlorine solution were feasibly integrated into recent vaccination campaigns.36,38–40,44–46 
We also found that there were substantial differences in how the campaigns were reported 
making comparisons difficult. A more systematic approach to decision-making – such as a rapid 
assessment tool – and a standardized method for data collection, monitoring and evaluation 
should be pursued, supported and published. This will ensure appropriate documentation of 
future campaigns. 
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Table 1. Oral cholera vaccines, 2014 
Vaccine Dukoral11 ORC-Vax and 
mORC-Vax11,12 
Shanchol11 
Manufacturer Crucell (the 
Netherlands) 
Vabiotech (Viet 
Nam) 
Shantha 
Biotechnics Ltd 
(India) 
Description Monovalent inactivated 
vaccine 
Bivalent 
inactivated vaccine 
Bivalent inactivated 
vaccine 
Components Killed whole-cells of V. 
cholerae O1 (Classical 
and El Tor biotypes) 
and recombinant B-
subunit of cholera toxin 
Killed whole cells 
of V. cholerae O1 
(Classical and El 
Tor biotypes) and 
V. cholerae O139 
Killed whole cells of 
V. cholerae O1 
(Classical and El 
Tor biotypes) and 
V. cholerae O139 
Recommende
d age 
2 years and older 1 year and older 1 year and older 
Delivery Oral Oral Oral 
Doses Two doses ≥ 1 week 
apart 
Two doses 
≥ 2 weeks apart 
Two doses 
≥ 2 weeks apart 
Buffer Yes. Buffer dissolved in 
75 mL (2–6 years old) 
or 150 mL (> 6 years 
old) water 
Not required Not required 
Booster dose Every 2 years (every 
6 months for children 2–
5 years) 
Every 3 years Every 3 years 
Licensure International (1991) Viet Nam 
(1997/2009) 
India (2009) 
WHO pre-
qualification 
Yes (2001) No Yes (2011) 
Storage 
temperature 
2–8 °C 2–8 °C 2–8 °C 
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Table 2. Characteristics and main findings of post-licensure oral cholera vaccination campaign studies, 1997–2014 
Vaccine 
and year of 
the 
campaign 
Site Setting Type and purpose of 
the vaccination 
campaign 
Eligibility 
criteria 
Target 
population, 
No. 
Coverage Main findings 
Received 1st 
dose, No. (%) 
Received 2nd 
dose, No. (%) 
Dukoral 
        
1997 Adjumani 
district, 
Uganda 
Refugee 
camp, rural 
Pre-emptive vaccination 
to assess feasibility in a 
stable refugee camp 
setting16,17 
≥ 1 year old 44 000 35 613 (81) 27 607 (62) Oral cholera vaccination of a 
large refugee population is 
feasible.16 During a cholera 
epidemic in the area the following 
year, cholera attack rates were 
0.59% in the non-refugee 
Ugandan villages, 0.04% in the 
30 non-vaccinated refugee 
camps and 0.00% in the six 
vaccinated refugee camps17 
2000 Mayotte 
Island, 
Comoros 
Urban and 
rural 
Pre-emptive vaccination 
campaign to prevent a 
cholera epidemic18 
N/A 145 000 NA 93 000 (64) N/A 
2003–2004 Beira, 
Mozambiqu
e 
Urban Pre-emptive vaccination 
in an endemic area with 
seasonal outbreaks. 
Effectiveness study in an 
HIV-endemic sub-
Saharan African site20,21 
Non-
pregnant, 
≥ 2 years old 
19 550 14 164 (72) 11 070 (57) Mass vaccination was feasible 
but required considerable logistic 
support and planning.20 One or 
more doses conferred 78% 
protection (95% CI: 39–92) 
against cholera during the year 
post vaccination21 
2004 South 
Darfur, 
Sudan 
Refugee 
camp, rural 
Pre-emptive vaccination 
to assess feasibility 
during the acute phase of 
an emergency (i.e. 
refugee camp of 
internally displaced 
persons)22,23 
≥ 2 years old 45 825 42 502 (93) 40 330 (88%) Although planning and 
implementation requirements 
were significant, the campaign 
was successful because of the 
strong support and commitment 
of the refugee community and 
collaborators22,23 
2005 Aceh, 
Indonesia 
Site of 
internally 
displaced 
persons 
Pre-emptive vaccination 
to assess feasibility 
during the acute phase of 
an emergency (i.e. post-
tsunami)23,24 
≥ 2 years old 78 870 62 505 (79%) 54 627 (69%) Challenges in the coordination, 
heavy logistics and frequent 
aftershocks complicated and 
delayed implementation. 
Difficulties in maintaining cold 
chain resulted in 11.7% vaccine 
losses23,24 
Publication: Bulletin of the World Health Organization; Type: Systematic reviews 
Article ID: BLT.14.139949 
Page 17 of 25 
2009 Zanzibar, 
the United 
Republic of 
Tanzania 
Urban and 
rural  
Pre-emptive vaccination 
in an endemic area with 
seasonal outbreaks. 
Effectiveness study to 
measure direct and 
indirect protection27–29 
Non-
pregnant, 
≥ 2 years old 
48 178 27 678 (57%) 23 921 (50%) Confirmed direct vaccine 
effectiveness of 79% (95% CI: 
47–92). First study to show 
vaccine herd protection in an 
African setting: 75% (95% CI: 11–
93%) indirect protection in the 
higher coverage group compared 
with the lower coverage group27 
No evidence of a harmful effect of 
gestational exposure to the 
vaccine28 First use of personal 
digital assistants for direct data 
entry during a survey 
enumeration and mass 
vaccination29 
ORC-Vax and mORC-Vax 
      
1998–2012 Viet Nam Endemic 
urban and 
rural areas 
Pre-emptive and reactive 
vaccinations of children 
integrated into the 
country’s public health 
program34 
Non-
pregnant, 
≥ 1 year old 
≈10.9 million 
doses 
N/A N/A Viet Nam is the only country in 
the world to regularly use oral 
cholera vaccinations. Since 1997, 
the number of cholera cases in 
Viet Nam has declined, in 
association with increased 
vaccination use as well as 
improvements in socioeconomic 
and water and sanitation 
conditions34 
1998 and 
2000 
Hue, Viet 
Nam 
Urban and 
rural 
Pre-emptive vaccination 
campaign in a cholera-
endemic area. Study to 
assess long term 
effectiveness31,32 
Non-
pregnant, 
≥ 1 year old 
149 557 
(1998) and 
137 082 
(2000) 
In 1998: 
125 135 (84%) 
and in 
2000:104 706 
(76%) 
In 1998:118 703 
(79%) and in 
2000:103 226 
(75%) 
Mass immunization is feasibly 
administered through the public 
health system.31 Direct vaccine 
effectiveness 3 to 5 years after 
vaccination was 50% (95% CI: 9–
63)32 
2008 Hanoi, Viet 
Nam 
Urban Reactive vaccination 
campaign during an on-
going outbreak33 
Non-
pregnant, 
≥ 1 year old 
≈370 000 
> 10 years 
old 
N/A ≈80% vaccinated Protective effectiveness of 76% 
(95% CI: 5–94). First study to 
document reactive use of oral 
cholera vaccination during an 
outbreak33 
Shanchol 
        
2011 Odisha, 
India 
Rural Pre-emptive vaccination 
campaign and feasibility 
study35 
Non-
pregnant, 
≥ 1 year old 
51 488 31 552 (61%) 23 751 (46%) Feasible to vaccinate using 
governmental set-up35 
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2011 Dhaka, 
Bangladesh 
Endemic 
urban areas 
Pre-emptive vaccination. 
Cluster randomized 
study with three arms: 
vaccine, vaccine plus 
safe water and hand 
washing practice and no 
intervention36 
Non-
pregnant, 
≥ 1 year old 
172 754 141 839 (82%) 123 666 (72%) Feasible to us the national 
immunization setup.36 On-going 
study of vaccine effectiveness. 
2012 Port-au-
Prince, Haiti 
Urban Reactive vaccination 
campaign. Pilot study37 
≥ 1 year old 70 000 52 357 (75%) 47 540 (68%) Effort, community mobilization 
and organizational capacity 
needed for a successful 
campaign where there were 
logistical and security 
challenges37 
2012 Bocozel and 
Grand 
Saline, Haiti 
Rural Reactive vaccination 
campaign. Pilot study38–
41
 
≥ 1 year old N/A 45 417 41 238 The campaign integrated with the 
other components of cholera 
control was found to be feasible 
and acceptable38–41 
2012 Choiseul 
and 
Shortland, 
Solomon 
Islands 
Rural Pre-emptive vaccination 
campaign near an area 
with a cholera outbreak42 
Children 1–
14 years old 
in high-risk 
areas 
N/A 11 888 11 318 N/A 
2012 Tak 
Province, 
Thailand 
Refugee 
camps, 
rural 
Pre-emptive vaccination 
campaign with a 
knowledge, attitudes and 
practices survey43 
Non-
pregnant, 
≥ 1 year old 
43 968 36 325 (83%) 26 753 (61%) First use of Shanchol in a stable 
refugee camp setting43 
2012 Boffa and 
Forecariah 
regions, 
Guinea 
Rural Reactive vaccination 
campaign during an on-
going outbreak and 
feasibility study44–46 
≥ 1 year old ≈209 000 
(≈163 000 in 
Boffa and 
≈46 000 
Forecariah) 
172 544 143 706 (Based on 
administrative 
population figures, 
68% in Boffa and 
51% in Forecariah. 
Household survey 
immediately after 
campaign 76%.)44 
First use of Shanchol in sub-
Saharan Africa. The campaign 
was successful despite short 
preparation time, remote rural 
setting and highly mobile 
population.44,45 Protective 
effectiveness of 87% (95% CI: 
56–96)46 
2013 Maban 
county, 
South Sudan 
Refugee 
camps, 
rural 
Pre-emptive vaccination 
campaign in an area with 
escalating Hep E 
outbreak47,48 
≥ 1 year old 146 317 N/A 132 000 (> 85% by 
survey) 
The campaign was successful 
despite logistical challenges47,48 
2013 Petite Anse, 
Haiti 
Urban and 
rural 
Pre-emptive vaccination 
campaign in a cholera-
endemic areaa 
≥ 1 year old 110 000 N/A 80 000 N/A 
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2014 South 
Sudan 
Internally 
displaced 
persons 
camps 
Pre-emptive vaccination 
campaign49 
Non 
pregnant, 
≥ 1 year old 
152 000 125 311 (72%) 76 088 (awaiting 
coverage surveys) 
Humanitarian crisis. First use of 
global OCV stockpile, Fixed and 
mobile teams. Second round in 
one site was co-administered with 
meningitis vaccine49 
CI: confidence interval; Hep E: Hepatitis E; N/A, information not available. 
a
 Information obtained through personal communications with Kathryn Alberti, UNICEF, New York, USA. 
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Table 3. Logistics of oral cholera vaccination campaigns, 1997–2013 
Target 
population 
size 
Site, year Vaccine Max. days 
per round 
Total 
duration 
Delivery method Approximate 
doses 
delivered/day 
Staff 
< 50 000 Adjumani district, 
Uganda, 199716 
Dukoral 4 Just over 
1 month 
15 vaccination sites 250–1735 114 persons: 19 nurses/midwives, 21 
nursing aides, 44 community health 
workers and 30 persons without 
qualifications 
Esturro, Beira, 
Mozambique, 
2003–200420 
Dukoral 9 1 month Outposts in churches and schools 
8am–3pm 6 days/week 
Average 609 One supervisor and 15–23 members 
per outpost 
Zanzibar, the 
United Republic of 
Tanzania, 200927 
Dukoral 15 Just over 
1 month 
Eight vaccination posts on each 
of the two islands. 8 hours daily. 
N/A Local health care workers and 
villagers 
Aceh, Indonesia, 
200523,24 
Dukoral N/A 5 months Three-phase approach, three 
different geographical areas with 
approximately one month 
between each phase. Fixed 
vaccination sites with some door 
to door mop-up. 
100–250 4 members per team 
50 000 to 
100 000 
Odisha, India, 
201135 
Shanchol 3 1 month Vaccination booths within 10–15 
minute walking distance from 
villagers open 7am–5pm daily. 
N/A At each booth: 1 midwife and 5–6 
community health workers/volunteers 
City of God, Port-
au-Prince and 
Bocozel and Grand 
Saline, Artibonite 
Department, Haiti, 
201237,39 
Shanchol Urban: N/A 
Rural: 10 
3 months 
per site 
Urban: door to door pre-
registration and vaccination at 9 
fixed sites. 
Rural: fixed posts, mobile posts 
and door to door 
N/A Urban campaign: 500 staff, 75 teams 
of 4 workers, plus 15 supervisors 
Rural: 40 teams of 4 workers each led 
by 20 supervisors 
Viet Nam 1998 and 
200031,32 
ORC-Vax 9 1 month Specifically designated sites, also 
used by EPI. 90 sites. 
139 (max) 90 teams 
> 100 000 Viet Nam 200833 ORC-Vax 3 13 days Commune health centres N/A N/A 
Mirpur, Dhaka, 
Bangladesh 
201136 
Shanchol 3-day 
cycles 
One and 
half months 
Fixed outreach vaccination sites. 
Sixty vaccine clusters were 
grouped into five cycles. In each 
3-day vaccination cycle, 12 
clusters were covered. The teams 
then moved on to the next cycle 
and thus all clusters were 
covered two times in two rounds. 
900–1000 76 vaccinators, 220 volunteers and 12 
first line supervisors 
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Boffa and 
Forecariah regions, 
Guinea 20 12444,45 
Shanchol 6 3 months Decentralized semi-mobile 
strategy. Most sites in place for 
only 1 day. In rural areas, teams 
could cover three sites in one 
day. 
774 (avg) 43 teams of 9 to 20 people 
Maban county, 
South Sudan 
201347,48 
Shanchol 7 Just over 
1 month 
Semi-mobile strategy, fixed points 
for first days of round, then mix of 
fixed sites and mop-up for last 
days of round. Also, in each MSF 
clinic. 
1150 Teams of 10 people at each site, plus 
14 people per camp for mobilization 
EPI: Expanded Program on Immunization; MSF: Médecins Sans Frontières; N/A: not available; OCV: oral cholera vaccine. 
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Table 4. Cost of post-licensure oral cholera vaccinations, 1997–2013 
Cost Uganda, 
199716 
Mozambiquea, 
2003–200420 
Indonesia, 
200523,24 
United 
Republic of 
Tanzania, 
200930 
Indiaa, 
201135 
Bangladesh, 
201136 
Guinea, 
201245 
South 
Sudan, 
201347 
Oral cholera vaccine Dukoral Dukoral Dukoral Dukoral Shanchol Shanchol Shanchol Shanchol 
Price per vaccine dose, US$ Free Free 4.70 5.00 2.22 1.00 1.85c 2.40c 
Number fully immunized 
persons 
27 607 44 156 54 627 23 921 23 751 123 666 143 706 71 912 
Vaccine and/or international 
shipment costs, US$ 
4 421 6 608 665 247 555 000 122 629 284 529 632 782c 661 690c 
Computers and other capital 
expenses, US$ 
1 600 900 4 738 N/A N/A N/A N/A N/A 
International consultants, US$ N/A N/A 124 230 110 000 N/A N/A N/A 133 917c 
Local storage and transport, 
US$ 
3 239 33 510 5 159 N/A 2 081 43 701 175 930c 115 428c 
Meetings, community 
mobilization, training, local 
salaries, supplies and waste 
management, US$ 
5 395 54 269 159 275 87 500 20 625b 157 932 106 630c 171 766c 
Adverse event following 
immunization monitoring and 
management, US$ 
N/A N/A N/A N/A 4 237 N/A N/A N/A 
Total cost for the vaccination 
campaign, US$ 
14 655 
(0.53) 
95 287 (2.16) 958 649 
(17.55) 
752 500 (31.46) 149 572 
(6.30) 
486 162 (3.93) 915 342 
(6.37)c 
1 082 801 
(15.06)c 
Total local delivery cost (per 
person), US$d 
14 655 
(0.53) 
88 679 (2.01) 169 172 (3.10) 87 500 (3.66) 26 943 (1.13) 201 633 (1.63) 282 560 
(1.97)c 
287 197 
(3.99)c 
N/A: not available; US$: United States dollar. 
a
 Including vaccinations outside the study target population 
b
 Itemized as follows: Social mobilization US$ 5603 and vaccine administration US$ 15 022 
c
 Costs originally reported in Euro. US$ was calculated using the conversion rate as of 1 February 2013: 1 Euro to US$ 1.37. 
d
 Excluding vaccine, international shipment and consultant costs. 
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Fig. 1. Flowchart for the selection of documents on oral cholera vaccination 
campaigns 
 
 
 
203 articles identified 
through database 
searches 
165 articles after 
duplicates removed 
165 articles assessed for 
eligibility 
140 articles excluded 
that did not fulfil 
inclusion criteria 
25 articles included 
9 documents identified 
through Google 
searches and included 
 2 meeting or 
briefing reports 
and presentations 
 4 international 
organization 
documents 
 2 company 
memos 
 1 local research 
article 
34 documents 
analysed 
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Fig. 2. Post-licensure oral cholera vaccination campaigns, 1997–2014 
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Fig. 3. Administration of Dukoral or Shanchol in post-licensure oral cholera 
vaccination campaigns globally, 1997–2014 
 
 
